Target intelligence / Profile preview

Protein kinase cAMP-dependent type I regulatory subunit beta (PRKAR1B)

Target
PRKAR1B
Molecular classification
Enzyme, Protein kinase regulatory subunit, Signal transduction protein, cAMP-binding protein, Member of the protein kinase A (PKA) family
01

Overview

Protein kinase cAMP-dependent type I regulatory subunit beta (PRKAR1B) is a key regulatory subunit of the PKA holoenzyme, which mediates cellular responses to cAMP. The PKA holoenzyme consists of two regulatory subunits (including PRKAR1B as RIβ) and two catalytic subunits. Upon cAMP binding, the complex dissociates, allowing the catalytic subunits to phosphorylate diverse protein targets. PRKAR1B is most highly expressed in the nervous system, especially cerebral cortex and hypothalamus, and its dysfunction causes neurodevelopmental disorders and contributes to tumorigenesis in some contexts. It serves as a cAMP receptor within the cell and anchors the PKA complex to specific subcellular locations via AKAP proteins, modulating key processes such as metabolism, ion transport, transcription, and neuronal signaling

Other names
PRKAR1BProtein kinase cAMP-dependent type I regulatory subunit betacAMP-dependent protein kinase type I-beta regulatory subunitProtein kinase, cAMP-dependent, regulatory subunit type I betaProtein kinase, cAMP-dependent, regulatory, type I, betaPRKAR1MASNSRIβprotein kinase cAMP-dependent type 1 regulatory subunit beta
02

Mechanism of action

Drugs that **modulate PKA activity** (by influencing cAMP levels, such as agonists of Gs-coupled GPCRs, PDE inhibitors, or adenylyl cyclase activators) indirectly affect PRKAR1B function as part of the PKA holoenzyme

03

Biological functions

Signal transduction (cAMP pathway/second messenger signaling)Regulation of metabolismIon transportTranscriptional regulationCellular localization of PKA activity
04

Disease associations

Neurodevelopmental disorders (including autism spectrum disorder, apraxia, pain insensitivity)Neurodegenerative disordersAdrenal tumorigenesis (possible role in adrenocortical disease, bilateral adrenal hyperplasia, and cortisol-producing adenomas)Marbach-Schaaf neurodevelopmental syndrome
05

Safety considerations

Therapeutic targeting of the cAMP/PKA axis may result in widespread effects, affecting metabolism, neuronal signaling, and cardiovascular function due to PKA's ubiquitous role in signaling
06

Interacting drugs

Forskolin (indirect)

1 more in the full profile.

07

Biomarkers

Genetic variants in PRKAR1B may serve as diagnostic biomarkers for neurodevelopmental disorders and adrenal hyperplasia

Beyond the preview

Go deeper on Protein kinase cAMP-dependent type I regulatory subunit beta (PRKAR1B).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Protein kinase cAMP-dependent type I regulatory subunit beta (PRKAR1B).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call